Cargando…

MP29-02* reduces eosinophil survival induced by epithelial cell secretions from nasal mucosa

Detalles Bibliográficos
Autores principales:	Roca-Ferrer, Jordi, Pujols, Laura, Pérez-Gonzalez, Maria, Alobid, Isram, Valero, Antonio, Picado, Cesar, Murray, Ruth, Mullol, Joaquim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493529/ http://dx.doi.org/10.1186/2045-7022-5-S4-P9

Ejemplares similares

Effect of Lipopolysaccharide on Glucocorticoid Receptor Function in Control Nasal Mucosa Fibroblasts and in Fibroblasts from Patients with Chronic Rhinosinusitis with Nasal Polyps and Asthma
por: Fernández-Bertolín, Laura, et al.
Publicado: (2015)

Mometasone and desloratadine additive effect on eosinophil survival and cytokine secretion from epithelial cells
por: Mullol, Joaquim, et al.
Publicado: (2011)

Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers
por: Roca-Ferrer, Jordi, et al.
Publicado: (2018)

Signal Transduction Pathways (MAPKs, NF-κB, and C/EBP) Regulating COX-2 Expression in Nasal Fibroblasts from Asthma Patients with Aspirin Intolerance
por: Garcia-Garcia, Francesc Josep, et al.
Publicado: (2012)

Effect of MP‐AzeFlu compared to monotherapy on COX‐2, PGE(2), and EP2 gene expression in upper airway mucosa
por: Vicens‐Artes, Sonia, et al.
Publicado: (2022)

Superior effect of MP‐AzeFlu compared to monotherapy with fluticasone propionate or azelastine on GILZ, MKP‐1 and TTP anti‐inflammatory gene expression in healthy and inflamed upper airway mucosa
por: Vicens‐Artés, Sònia, et al.
Publicado: (2022)

132 Characterization of 2 Epithelial Cell Air-Liquid Interface (ALI) Culture Models for Human Healthy Nasal Mucosa and Nasal Polyps
por: de Borja Callejas, Fco, et al.
Publicado: (2012)

133 Corticosteroid Rreatment Reduces Tissue Eosinophilia and the Expression of Matrix Metalloproteinases (MMP-1, MMP-2, MMP-7, MMP-9) and Their Tissue Inhibitor (TIMP-1) in Nasal Polyps
por: de Borja Callejas, Fco, et al.
Publicado: (2012)

Reconstituted Human Upper Airway Epithelium as 3-D In Vitro Model for Nasal Polyposis
por: de Borja Callejas, Francisco, et al.
Publicado: (2014)

A new allergic rhinitis therapy (MP29-02*) provides effective and rapid symptom relief for patients who suffer most from the bothersome symptoms of nasal congestion or ocular itch
por: Fokkens, Wytske, et al.
Publicado: (2015)

A new intranasal therapy (MP29-02*) is more effective than current firstline therapy regardless of season, symptom or severity.
por: Bachert, Claus, et al.
Publicado: (2015)

Deposition characteristics of a new allergic rhinitis nasal spray (MP29-02*) in an anatomical model of the human nasal cavity
por: D’Addio, Alex, et al.
Publicado: (2015)

A new therapy (MP29-02*) effectively controls nasal symptoms of seasonal allergic rhinitis irrespective of severity
por: Scadding, Glenis, et al.
Publicado: (2013)

Reference Gene Validation for RT–qPCR in PBMCs from Asthmatic Patients with or without Obesity
por: Bantulà, Marina, et al.
Publicado: (2022)

Fibrinolytic components in nasal mucosa and nasal secretion
por: Yasuda, Toyotoshi, et al.
Publicado: (1998)

A new AR therapy (MP29-02*): all of ARIA in one puff
por: Mösges, Ralph, et al.
Publicado: (2015)

A new therapy (MP29-02*) provides effective relief from all individual nasal and ocular symptoms of seasonal allergic rhinitis
por: Hellings, Peter, et al.
Publicado: (2013)

Evaluation of nasal symptoms induced by platelet activating factor, after nasal challenge in both healthy and allergic rhinitis subjects pretreated with rupatadine, levocetirizine or placebo in a cross-over study design
por: Muñoz-Cano, Rosa, et al.
Publicado: (2013)

Real-life effectiveness of a new allergic rhinitis therapy (MP29-02*) in Sweden
por: Stjärne, Pär, et al.
Publicado: (2015)

The effect of MP29-02* is mediated via bitter taste receptors (TAS2R)
por: Ekstedt, Sandra, et al.
Publicado: (2015)

551 The Impact of Nasal Polyposis on Quality of Life Using the Eq-5d Health Profile
por: Alobid, Isam, et al.
Publicado: (2012)

A new allergic rhinitis therapy (MP29-02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies
por: Hellings, Peter, et al.
Publicado: (2015)

Prostaglandin E2 receptors in asthma and in chronic rhinosinusitis/nasal polyps with and without aspirin hypersensitivity
por: Machado-Carvalho, Liliana, et al.
Publicado: (2014)

Management of Mechanical Nasal Obstruction Isolated or Associated to Upper Airway Inflammatory Diseases in Real Life: Use of both Subjective and Objective Criteria
por: Merma-Linares, Carla, et al.
Publicado: (2023)

Furthering the understanding of olfaction, prevalence of loss of smell and risk factors: a population-based survey (OLFACAT study)
por: Mullol, Joaquim, et al.
Publicado: (2012)

A new therapy (MP29-02*) effectively treats patients with seasonal allergic rhinitis who suffer most from the bothersome nasal symptom of congestion
por: Bachert, Claus, et al.
Publicado: (2013)

Short and long-term safety of MP29-02*: a new therapy for the treatment of allergic rhinitis
por: Price, David, et al.
Publicado: (2013)

Differences in Inflammatory Cytokine Profile in Obesity-Associated Asthma: Effects of Weight Loss
por: Bantulà, Marina, et al.
Publicado: (2022)

A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex
por: Price, David, et al.
Publicado: (2013)

Chronic rhinosinusitis with nasal polyps and allergic rhinitis as different multimorbid treatable traits in asthma
por: Castillo, José Antonio, et al.
Publicado: (2023)

Overuse of diagnostic tools and medications in acute rhinosinusitis in Spain: a population-based study (the PROSINUS study)
por: Jaume, Francesca, et al.
Publicado: (2018)

Nasal polyps, aspirin sensitivity, and late onset asthma are crucial to identify severe asthma. clinicaltrials.gov id : nct01513837
por: Castillo, José A, et al.
Publicado: (2015)

Effect of Obesity on the Expression of Genes Associated with Severe Asthma—A Pilot Study
por: Bantulà, Marina, et al.
Publicado: (2023)

MP29-02*’s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis
por: Scadding, Glenis, et al.
Publicado: (2015)

PD15 - MP29-02 effectively relieves both nasal and ocular symptoms in adolescents aged 12-17 years: results from a meta-analysis of 4 randomised controlled Seasonal Allergic Rhinitis (SAR) trials
por: Valovirta, Erkka, et al.
Publicado: (2014)

Nasal polyps in patients with asthma: prevalence, impact, and management challenges
por: Langdon, Cristobal, et al.
Publicado: (2016)

CD25(+) T-lymphocytes induce CD11b on eosinophils in allergic nasal mucosa
por: Horiguchi, S., et al.
Publicado: (1995)

Reply
por: Mullol, Joaquim, et al.
Publicado: (2020)

Lung Myofibroblasts Are Characterized by Down-Regulated Cyclooxygenase-2 and Its Main Metabolite, Prostaglandin E2
por: Gabasa, Marta, et al.
Publicado: (2013)

Olfactory dysfunction during COVID-19 pandemic()
por: Izquierdo-Domínguez, Adriana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bvpjcaca08p0lcmnk04f2ffb5m